Inflammatory bowel diseases in anti-neutrophil cytoplasmic antibody-associated vasculitides: 11 retrospective cases from the XXXX Study Group.

@entity1 @entity1333 @entity12534 @entity31 @entity1198 @entity8787 @entity2883 @entity30 @entity19417
OBJECTIVE: Coexistence of @entity19417 ( @entity19417 ) and @entity8787 is a rare condition that is rarely described in the literature. The aim of the study was to describe the main characteristics of @entity1 presenting with both @entity8787 and @entity19417 . METHODS: A retrospective study of @entity19417 @entity1 in the @entity1333 Study Group cohort who also had a diagnosis of @entity8787 was conducted. We reviewed the medical records and outcomes of these @entity1 . RESULTS: We identified 11 @entity1 with @entity19417 and @entity8787 . Four @entity1 with eosinophilic @entity2883 with @entity2883 ( @entity12534 ) also had @entity31 and seven @entity1 with @entity2883 with @entity2883 (GPA) had @entity30 . No @entity30 was observed in eosinophilic GPA and no @entity31 in GPA. @entity8787 started before @entity19417 manifestations in six cases, simultaneously in two cases and after @entity19417 manifestations in three cases. CONCLUSION: Coexistence of @entity8787 and @entity19417 is a rare condition. The therapeutic management of these @entity1 includes corticosteroids in all cases and immunosuppressive drugs in some @entity1 . Coexistence of @entity8787 and @entity19417 might be explained by common underlying inflammatory responses and cytokine profiles polarized towards either @entity1198 or Th2. Finally, in the presence of digestive manifestations in the context of @entity19417 , the hypothesis of @entity8787 should be assessed.
